Sonnet BioTherapeutics is no longer just a cancer drug developer. Its $888 million merger will place it among the largest HYPE holders, blurring the lines between traditional finance and decentralized protocols in a high-stakes treasury experiment. According to a July…
Related Posts
BONK approaches critical apex: Double Bottom formation in play
BONK is trading at a key high time frame support level while showing signs of a potential trend…
EigenLayer’s EigenDA to support layer-2 native token restaking
Users will be able to earn restaking yield from layer-2 tokens on EigenDA.
ETH whales signal strategic shift after tracking early Remittix adoption across mobile wallet systems
As Ethereum faces delays, Remittix gains traction with a live wallet and top CertiK security ranking. As Friday…